1. US FDA. Dupixent® (dupilumab) injection, for subcutaneous use: US prescribing information. 2017.
https://www.fda.gov
. Accessed 02 May 2017.
2. Sanofi. Sanofi and Regeneron announce FDA approval of Dupixent® (dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis (media release). 2017.
http://mediaroom.sanofi.com/press-releases/
. Accessed 02 May 2017.
3. Sanofi. Sanofi and Regeneron announce Marketing Authorization Application for Dupixent® (dupilumab) accepted for review by the EMA (media release). 2016.
http://mediaroom.sanofi.com/press-releases/
. Accessed 02 May 2017.
4. Sanofi. UK patients granted early access to Sanofi’s innovative dermatology treatment dupilumab by MHRA (media release). 2017.
http://www.sanofi.co.uk
. Accessed 02 May 2017.
5. Regeneron Pharmaceuticals. Regeneron reports third quarter 2016 financial and operating results (media release). 2016.
http://newsroom.regeneron.com/releases.cfm?view=all
. Accessed 02 May 2017.